A Randomized Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Rheumatoid Arthritis
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Have a diagnosis of adult-onset Rheumatoid Arthritis (RA)
- If RA symptom onset is <6 months, are rheumatoid factor or anticitrullinated antibody positive
- Be clinically suitable, in the investigator's opinion, to receive a targeted therapy
- Have moderately to severely active Rheumatoid Arthritis (RA)
- Have had an IR or intolerance to at least 1 DMARD (synthetic or biologic)
- Have at least one of the following 4 characteristics:
- Documented evidence of a VTE prior to this study
- Age =60 years
- BMI =30 kg/m2
- Age 50 to <60 years AND BMI 25 to <30 kg/m2
- Abstinent or use 1 highly effective method of contraception
- Provide written informed consent
You may not be eligible for this study if the following are true:
-
- Have any contraindications to a TNF inhibitor
- Are pregnant or breastfeeding
- Have a history of VTE (DVT/PE) within 12 weeks prior to randomization
- Have active primary or recurrent malignant disease or have been in remission from clinically significant malignancy for <5 years prior to randomization
- Have active herpes zoster
- Have a clinically serious infection or have any other active or recent infection that, in the opinion of the investigator, would pose an unacceptable risk to the participant
- Have a history or presence of any illness that, in the opinion of the investigator, could pose an unacceptable risk to the participant
- Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB
- Have evidence of active TB or untreated/inadequately/inappropriately treated for latent TB
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.